The side effects of the three treatment groups were similar to previously reported effects for androgen-deprivation therapy. SC Degarelix was associated with a higher rate of injection-site reactions than with IM leuprorelin (40% vs < 1%; P<0.001). There were additional differences between the degarelix and leuprorelin groups for urinary tract infections (3% vs 9%; P<0.01), arthralgia (4% vs 9%; P<0.05) and chills (4% vs 0%; P<0.01).r
Cardiovascular side effects were reported by 13% and 9% of patients in the leuprorelin and degarelix groups respectively.r
There is currently no safety data on degarelix beyond 12 months and so the long term effects (cardiovascular complications and effects on bone mineral density) is not known.
© British Journal of Urology International 2008